

TITLE: BEYOND BONES - THE RELEVANCE OF VARIANTS OF CONNECTIVE TISSUE (HYPERMOBILITY) TO FIBROMYALGIA, ME/CFS AND CONTROVERSIES SURROUNDING DIAGNOSTIC CLASSIFICATION: AN OBSERVATIONAL STUDY

AUTHORS' NAMES: Jessica A Eccles (0000-0002-0062-1216), Beth Thompson , Kristy Themelis, Marisa Amato, Robyn Stocks, Amy Pound, Anna-Marie Jones, Zdenka Cipinova, Lorraine Shah-Goodwin, Jean Timeyin, Charlotte R Thompson, Thomas Batty, Neil A Harrison, Hugo D Critchley, Kevin A Davies

AUTHORS' DETAILS: Department of Neuroscience, Brighton and Sussex Medical School, Falmer, United Kingdom, Clinical Investigation & Research Unit (CIRU), Brighton and Sussex University Hospitals NHS Trust, United Kingdom, Immunopsychiatry Service, Sussex Partnership Foundation NHS Trust, United Kingdom Jessica Eccles Senior Clinical Lecturer, Department of Neuroscience, Brighton and Sussex Medical School, Falmer, United Kingdom Beth Thompson medical student Department of Neuroscience, Brighton and Sussex Medical School, Falmer, United Kingdom, Clinical Investigation & Research Unit (CIRU), Brighton and Sussex University Hospitals NHS Trust, United Kingdom Kristy Themelis post doctoral research fellow Department of Neuroscience, Brighton and Sussex Medical School, Falmer, United Kingdom Marisa Amato PhD student Department of Neuroscience, Brighton and Sussex Medical School, Falmer, United Kingdom Robyn Stocks medical student Department of Neuroscience, Brighton and Sussex Medical School, Falmer, United Kingdom, Research and Development, Sussex Partnership

Foundation NHS Trust, United Kingdom Amy Pound research assistant Research and Development, Sussex Partnership Foundation NHS Trust, United Kingdom Anna-Marie Jones, statistician Clinical Investigation & Research Unit (CIRU), Brighton and Sussex University Hospitals NHS Trust, United Kingdom Zdenka Cipinova research nurse Clinical Investigation & Research Unit (CIRU), Brighton and Sussex University Hospitals NHS Trust, United Kingdom Lorraine Shah-Goodwin research nurse Clinical Investigation & Research Unit (CIRU), Brighton and Sussex University Hospitals NHS Trust, United Kingdom Jean Timeyin research nurse Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Falmer, United Kingdom, Clinical Investigation & Research Unit (CIRU), Brighton and Sussex University Hospitals NHS Trust, United Kingdom, Department of Rheumatology, Brighton and Sussex University Hospitals NHS Trust, United Kingdom Charlotte Thompson, senior clinical lecturer in rheumatology Brighton and Sussex University Hospitals NHS Trust, United Kingdom, Department of Rheumatology, Brighton and Sussex University Hospitals NHS Trust, United Kingdom, . Department of Medical Education, Brighton and Sussex Medical School, Falmer, United Kingdom Department of Neuroscience, Brighton and Sussex Medical School, Falmer, United Kingdom Thomas Batty medical education fellow Department of Neuroscience, Brighton and Sussex Medical School, Falmer, United Kingdom, Immunopsychiatry Research Group, Cardiff University Brain Research Imaging Centre, Maindy Road, Cardiff, United Kingdom Neil Harrison professor Department of Neuroscience, Brighton and Sussex Medical School, Falmer, United Kingdom, Sackler Centre for Consciousness Science, University of Sussex, Falmer, United Kingdom, Neurobehavioural Service, Sussex Partnership NHS Foundation Trust, Brighton, United Kingdom Hugo Critchley, chair in psychiatry Department of Clinical

and Experimental Medicine, Brighton and Sussex Medical School, Falmer, United Kingdom, Clinical Investigation & Research Unit (CIRU), Brighton and Sussex University Hospitals NHS Trust, United Kingdom, Department of Rheumatology, Brighton and Sussex University Hospitals NHS Trust, United Kingdom Kevin Davies chair in medicine

Correspondence to Dr Jessica A Eccles

Trafford Centre for Medical Research

University of Sussex

BN1 9RY

j.eccles@bsms.ac.uk

01273 877700

WORD COUNT 2,817

ABSTRACT

- **Objectives** –To understand the relevance of symptomatic hypermobility and related connective tissue variants to the expression of symptoms in Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The study further tested if specific subfactors within the diagnostic classification of hypermobility predict clinical presentations.
- **Design** – We report part of a larger case-control study exploring mechanisms of chronic pain and fatigue in Fibromyalgia and ME/CFS (<https://doi.org/10.1186/ISRCTN78820481>)
- **Setting** – an NHS Clinical Research Facility.
- **Participants** – A subsample of 87 participants were assessed for symptomatic hypermobility by a trained clinician: 63 presented with a clinical diagnosis of either Fibromyalgia and or ME/CFS confirmed at screening; 24 participants were confirmed as healthy controls.
- **Main outcome measures** – 1) Brighton Criteria for joint hypermobility syndrome and 2017 hEDS diagnostic criteria. 2) ACR 2010 Diagnostic Criteria for Fibromyalgia and Canadian and Fukada diagnostic criteria for ME/CFS. 3) Self report measures of subjective pain, fatigue and interoceptive sensibility.
- **Results** – Twenty of the 63 patients (32%) presented with a clinical diagnosis of Fibromyalgia; 24 (38%) with a clinical diagnosis of ME/CFS and 19 (30%) with dual diagnoses of fibromyalgia and ME/CFS. After evaluation using clinical research tools, 56 patients (89%) met ACR diagnostic criteria for fibromyalgia; 59 (94%) Canadian Criteria for ME/CFS; and 61 (97%) Fukada Criteria for ME/CFS. After research evaluation 52 patients (85%) in fact met diagnostic criteria for Fibromyalgia and ME/CFS on all three sets of tools (ACR, Canadian, Fukada). In addition, 51

patients (81%) and 9 (37.5%) healthy controls met Brighton Criteria for joint hypermobility syndrome and 11 (18%) and 2 (8%) of patients and controls respectively, on the 2017 hEDS criteria. Of these patient participants with symptomatic hypermobility only 12 (23.5%) had received a prior diagnosis of hypermobility.

Across all participants meeting Brighton Criteria, 13 (22%) also endorsed a hEDS diagnosis. Membership of the patient group was predicted by meeting the Brighton Criteria for joint hypermobility syndrome ($p < 0.001$, OR 7.08, 95%CI 2.50 – 20.00), but not by meeting the hEDS criteria. The historical, rather than current Brighton score correlated with; 1) total pain reported on the McGill Pain Questionnaire (short form), ($r = 0.25$, $n = 73$, $p = 0.03$); 2) Widespread Pain Index (derived from ACR diagnostic criteria) ($r = 0.26$, $n = 86$, $p = 0.01$); 3) ACR symptom severity ($r = 0.27$, $n = 85$, $p = 0.01$); 4) Fatigue Impact ($r = 0.29$, $n = 56$, $p = 0.28$); and 5) interoceptive sensibility ($r = 0.30$, $n = 56$, $p = 0.02$).

• **Conclusions** – Symptomatic joint hypermobility is relevant to symptoms and diagnosis in Fibromyalgia and ME/CFS. These conditions are poorly understood yet have a considerable impact on quality of life. Further work is needed to determine the prevalence of hEDS within the general population and define the critical clinical dimensions within symptomatic hypermobility. It is important to note the high rates of mis/underdiagnosis of symptomatic hypermobility in this group. Moreover, we need to clarify the role of variant connective tissue in dysautonomic and inflammatory mechanisms implicated in the expression of pain and fatigue in fibromyalgia and ME/CFS. Our observations have implications for diagnosis and treatment targets.

• **Study registration** – ISCRTN78820481

INTRODUCTION

Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) have overlapping symptoms. Fibromyalgia is a common, poorly understood, complex musculo-skeletal disorder that affects around 5% of the UK population¹. It is polysymptomatic yet marked primarily by chronic widespread pain, typically believed to be non-inflammatory in nature. In addition, patients frequently report extra-musculoskeletal symptoms, including both physical and emotional fatigue with subjective cognitive dysfunction ('fibrofog'^{2,3}). For quality of life, patients with fibromyalgia score significantly lower than the general population², or patients with other musculo-skeletal disorders such as rheumatoid arthritis, osteoarthritis and SLE⁴, on all-eight health status domains. Pain, fatigue, subjective cognitive impairment and psychological disturbance (e.g. depression and anxiety)⁵ have greatest impact on quality of life. Thus, pain and fatigue are identified as among the most disabling symptoms associated with fibromyalgia. Relatedly, pain is also frequently reported in ME/CFS^{6,7}. Complexity to understanding their origins may have contributed at times to consideration of both fibromyalgia and ME/CFS as functional somatic, medically-unexplained, or somatisation disorders. The presence of shared symptoms in brain and body has also fuelled debate as to whether fibromyalgia and ME/CFS are manifestations of the same spectrum disorder or separate clinical entities^{8,9}. Although the dominant symptom of fibromyalgia is pain and ME/CFS is disabling fatigue or post-exertional malaise, patients with either diagnosis typically experience pain (including hyperalgesia and central sensitisation), fatigue, sleep problems and cognitive difficulties⁹. Altered inflammatory markers^{10,11} and dysautonomia¹²⁻¹⁴ are reported in both fibromyalgia and ME/CFS, calling into question their perceived status as 'functional' disorders. Moreover, it is increasingly

recognized that fibromyalgia¹⁵ and ME/CFS^{5 16 17} are associated with joint hypermobility¹⁸⁻²¹, an expression of variant connective tissue. In this context, most patients (82.6%) with Ehlers Danlos Syndrome –Hypermobility Type (EDS-HT) /Joint Hypermobility Syndrome patients (JHS) meet criteria for ME/CFS, compared to only 8.4% of controls²². Beighton (hypermobility) scores are higher in children with a ME/CFS diagnosis than gender-matched controls²³. Similarly, criteria for joint hypermobility is reportedly met by 64.2% women with fibromyalgia compared to only 22% of controls²⁴. Clinicians may diagnose hypermobility as fibromyalgia, since widespread pain is a key feature of both conditions²⁵.

Joint hypermobility (including Ehlers-Danlos Syndrome(s))¹⁸⁻²¹ is common^{26 27} and associated with many extra-articular features²⁸. Internationally, there is little agreement on the precise definition of measurement and hypermobility, nor the point at which it constitutes a disorder. In 2017, a consensus group sought to re-classify Ehlers Danlos Syndrome-Hypermobility Type (EDS-HT). As a consequence, the terms hEDS (hypermobile EDS) and Hypermobility Spectrum Disorder (HSD) now refer to symptomatic joint hypermobility²⁹. An earlier term, Joint Hypermobility Syndrome (diagnosed by Revised Brighton Criteria)³⁰ was made redundant and was previously deemed indistinguishable from EDS-HT³¹. However, one important distinction is that the Revised Brighton Criteria took into account historical joint hypermobility, whereas the newer criteria for hEDS rely on age and gender specific hypermobility cut-offs. A broader concept of a Hypermobility Spectrum Disorder (HSD) was introduced to describe the continuum that encompasses patients with symptomatic joint hypermobility through to people who do not meet full criteria for hEDS or related syndromes associated with joint hypermobility. However, this notion

of a spectrum also remains controversial. Since there are no genetic tests available for hEDS, a clinical diagnostic checklist is available and consistent with the 2017 consensus criteria²⁹. Further research is required to validate clinical diagnostic criteria and international diagnostic codes, which presently are not consistent with newer nomenclature. In adults with hEDS/HSD, symptoms (including pain, fatigue, dysautonomic symptoms, co-ordination, attention/concentration deficits and quality of life in general) can be also classified according to severity, reflecting neither the old or new criteria for hEDS³². Debate regarding diagnostic classification has intensified following a report on the prevalence of EDS and JHS in primary care that suggests these diagnoses cannot be considered rare³³. Moreover, symptomatic hypermobility has considerable impact on quality of life, at least comparable or greater than those with other rheumatological diseases.³⁴⁻⁴⁵

The morbidity of hEDS/HSD to patients is most commonly expressed as complaints to clinicians of chronic musculoskeletal pain, headache and fatigue. These symptoms impair physical activity and quality of life³⁴⁻⁴⁵, common to both Fibromyalgia and ME/CFS. In rheumatology clinics, symptomatic hypermobility is estimated to contribute to nearly half of all outpatient appointments, but is only recognised 1 out of 19 times⁴⁶. Under-diagnosis of hEDS/HSD may exacerbate potentially disabling symptoms complications⁴⁷ and comorbidities, including autonomic dysfunction^{14 48}, fibromyalgia²⁴ and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)⁴⁹. Enhanced recognition of symptomatic hypermobility is essential to improve function and quality of life in a patient group, whose symptoms are typically poorly understood and frequently overlooked⁴⁶. Accurate phenotyping of hEDS/HSD is needed for research, but it is also critical to effective

multi-disciplinary clinical management, from provision of accurate prognostic advice and identification of co-morbidity, to the offer of multi-professional support and delivery of effective therapies. The relevance extends beyond rheumatology to other clinical contexts; e.g. cardiology, paediatrics, neurology, gastroenterology, pain management and mental health settings.

Aims of the study

The objective of this study was to understand the relevance of symptomatic hypermobility and related connective tissue variants to the expression of symptoms in Fibromyalgia ME/CFS. The study systematically tests associations between the diagnostic criteria for pain and fatigue symptom expression and further examines if specific sub factors within the diagnostic classifications of hypermobility predict clinical presentations.

METHODS

This study is part of larger study investigating mechanisms of chronic pain and fatigue in fibromyalgia and ME/CFS (<https://doi.org/10.1186/ISRCTN78820481>) in adults. This paper focuses on the relevance of symptomatic hypermobility. All participants (patient participants and healthy controls) provided written informed consent and were compensated for their participation.

Patient and public involvement

The study idea was formed after patients and prior research participants discussed their lived experience of fibromyalgia and ME/CFS with the clinicians involved in the initial grant application (JAE, NAH, KAD, HDC). A formal Patient and Public Involvement panel (Brighton and Sussex University Hospitals Trust JAFFA Panel)

reviewed the study after funding was obtained and advised on the study protocol and design, strategies for recruitment reflecting their priorities, experiences and preferences. Patients and public assessed the burden of testing and the time required to participate in the study. Patients and public were involved in the promotion of the study through local support groups for patients living with fibromyalgia and ME/CFS. Patients and public will be involved in supporting the dissemination of the study findings to participants and wider relevant communities

Patient participants with a clinical diagnosis of either fibromyalgia and/or ME/CFS were invited to be screened for the study. To be included in the study patients were required to either meet the American College of Rheumatology (ACR 2010)⁵⁰ diagnostic criteria for FM and/or both the Canadian⁵¹ and Fukada (CDC)⁵² Criteria for ME/CFS as assessed at screening. Patients were recruited by advertisement from local support organisations for Fibromyalgia and ME/CFS, local rheumatology clinics and via social media and bulletin boards. Inclusion criteria for healthy controls were as follows: A score no more than 3/10 on a pain visual analogue scale, a score of less than 36 on the Fatigue Severity Scale⁵³ and not meeting either the criteria for American ACR diagnostic criteria for fibromyalgia, or the Canadian and Fukada (CDC) Criteria for ME/CFS and be free of major psychiatric or neurological illness. Healthy controls were also recruited via social media and bulletin boards. Neither patients nor controls were recruited/ selected or screened on the basis of hypermobility.

In total, 24 healthy controls were assessed alongside 63 patient participants. Where possible controls were matched to age and gender of patient participants.

All participants who responded to advertisements were provided with more information. If they were willing to continue, there were screened via telephone or via anonymized online questionnaires for eligibility. Consenting participants completed a series of baseline questionnaires measuring subjective pain (McGill Pain short form Questionnaire⁵⁴); fatigue (Fatigue Impact⁵⁵, Modified Fatigue Impact Scale⁵⁶); brain-fog (Mental Clutter Scale⁵⁷) and interoceptive sensibility⁵⁸ (Porges Body Perception Questionnaire⁵⁹). Demographic data was also collected and participants were assessed for presence of symptomatic hypermobility and variants of connective tissue by trained clinicians using the revised Brighton Criteria and the 2017 hEDS classification criteria^{29 46}. It was not possible to determine the last item in criterion 2A (Aortic root dilatation with Z-score >+2) as participants did not undergo echocardiography as part of the study protocol.

Data analysis and statistical methods

Each symptomatic hypermobility diagnostic classification (revised Brighton Criteria for JHS; hEDS 2017 consensus criteria) were entered as binary variables. Further binary variables explored categorical elements of the different criteria. The Brighton Scale and total number of major and minor criteria endorsed were expressed as scale data. Differences between groups in age and assessment outcomes were assessed via independent sample t tests. Differences in sex and associations between groups were assessed via chi square test. Binary logistic regression was used to derive prediction models for categorical variables, their odds ratios and their confidence intervals where appropriate. Univariate analyses (General Linear Model) were used to determine interactions. Spearman correlations were used to explore

correlations with Beighton score. Hypothesis tests were considered statistically significant for p-values < 0.05 and all analyses were carried out using SPSS version 25 for Mac.

Results

Patient characteristics and diagnostic groups

Twenty-four healthy controls (9 male) and patients (12 male) did not differ significantly in age. Mean (SEM) age of all healthy controls (39.3 years, (2.7)) was not significantly different to the whole patient group (45.4, 1.9). There were no significant differences in sex.

Among the 63 patients, 20 (32%) presented with a clinical diagnosis of fibromyalgia; 24 (38%) presented with a clinical diagnosis of ME/CFS; and 19 (30%) presented with dual diagnoses of fibromyalgia and ME/CFS

On research diagnostic evaluation, 56 (89%) met ACR diagnostic criteria for fibromyalgia, 59 (94%) met Canadian Criteria for ME/CFS and 61 (97%) met Fukada Criteria for ME/CFS. Strikingly, . fifty-two patients (85%) met all three diagnostic criteria for fibromyalgia and ME/CFS (ACR, Canadian, Fukada).

Nine (37.5%) healthy controls met Brighton Criteria, compared to 51 (81%) of the patient group. Two (8%) of healthy controls met 2017 hEDS criteria, compared to 11 (18%) of the patients. Across all participants meeting Brighton Criteria, 13 (22%) endorsed a hEDS diagnosis. Of those assessed as having symptomatic hypermobility only 12 (23.5%) had received a diagnosis of hypermobility prior to evaluation in this study.

Relevance of symptomatic hypermobility to diagnosis

Brighton score

Across all participants there were no associations between current (i.e. present) Brighton score and baseline pain, fatigue and interoceptive questionnaires.

Historical Brighton score (i.e. ever being able to perform the relevant manoeuvre) correlated positively with total pain on McGill Pain short form Questionnaire⁵⁴ ($r=0.25$, $n=73$, $p=0.03$), Widespread Pain Index (derived from ACR diagnostic criteria) ($r=0.26$, $n=86$, $p=0.01$), ACR somatic symptom severity ($r=0.27$, $n=85$, $p=0.01$), Fatigue Impact ($r=0.29$, $n=56$, $p=0.28$), interoceptive sensibility ($r=0.30$, $n=56$, $p=0.02$) (all Spearman rank correlations).

There was a significant interaction of being a patient with fibromyalgia and/or ME/CFS compared to being a control on the relationship between historical Brighton score and McGill Pain Score ($F=5.50$, $p=0.022$); Widespread Pain Index ($F=36.87$, $p<0.001$); ACR somatic symptom severity ($F=59.74$, $p<0.001$); Fatigue Severity Scale ($F=35.29$, $p<0.001$); Fatigue Impact ($F=27.37$, $p<0.001$); Modified Fatigue Impact Scale ($F=37.01$, $p<0.001$); Mental Clutter Scale ($F=15.72$, $p<0.001$) (Univariate General Linear Model). This means that the relationship symptoms and being a patient and control was significantly different according to hypermobility score

Brighton Criteria for Joint Hypermobility Syndrome

1. Mixed Fibromyalgia/ME/CFS

Meeting Brighton Criteria significantly predicted membership of the patient group (OR 7.08, $p < 0.001$, 95%CI 2.50 – 20.00), and meeting both major criteria for the Brighton Criteria was significantly associated with being a patient ($\chi^2 = 9.26$, $p = 0.022$)

Easy bruising was significantly associated with being a patient rather than a control ($\chi^2 4.10$, $p = 0.043$). No other minor criteria were significantly predictive of group membership. There was a significant interaction of joint hypermobility syndrome on the relationship between interoceptive sensibility and group membership ($F = 8.75$, $p = 0.005$)

2. Fibromyalgia

Endorsing both major criteria of Brighton Criteria was significantly associated with an ACR fibromyalgia diagnosis ($\chi^2 6.53$, $p = 0.01$). ACR Fibromyalgia was associated with easy bruising, ($\chi^2 7.58$, $p = 0.006$). No other minor criteria were significantly predictive of fibromyalgia

3. ME/CFS

Endorsing both major criteria of Brighton Criteria was significantly associated with fulfilling Canadian criteria for ME/CFS ($\chi^2 7.64$, $p = 0.006$), as was endorsing Fukada Criteria ($\chi^2 10.50$, $p = 0.001$). Easy bruising ($\chi^2 4.22$, $p = 0.040$) was associated with both Canadian criteria for ME/CFS and Fukada Criteria ($\chi^2 5.71$, $p = 0.017$). No other minor criteria were significantly predictive of ME/CFS

4. Meeting all 3 diagnostic criteria (ACR, Canadian, Fukada)

Meeting Brighton Criteria for Joint Hypermobility Syndrome predicted meeting all three patient diagnostic criteria ($p < 0.001$, OR 8.57 95%CI 3.02 – 24.05)

hEDS 2017 Diagnostic Criteria

1. Mixed Fibromyalgia and or//ME/CFS

A diagnosis of hEDS did not predict presence of Fibromyalgia and or//ME/CFS, nor did individual elements of the diagnostic criteria

2. Fibromyalgia

There were no associations between ACR definition of fibromyalgia and hEDS diagnosis or elements of the diagnostic criteria

3. ME/CFS

Endorsing hEDS criterion 1 (age/sex adjusted Brighton score) significantly predicted presence of ME/CFS as defined by Canadian criteria ($p = 0.045$, OR 3.07 95% CI (1.01 – 9.28)), and the Fukada Criteria ($p = 0.031$ OR 3.70 95% CI 1.12 – 12.18) No other elements of the hEDS diagnostic criteria were significantly predictive

4. Meeting all 3 diagnostic criteria (ACR, Canadian, Fukada)

A diagnosis of hEDS did not significantly predict meeting all three criteria. Neither did any diagnostic element

DISCUSSION

The strength of this research study is that it is the first clinical evaluation to our knowledge, that incorporates and directly compares Brighton (Joint Hypermobility Syndrome) and hEDS criteria. This study demonstrates the overlapping nature of Fibromyalgia and ME/CFS within current diagnostic criteria, which remains controversial⁸⁻⁹. We show the contribution of symptomatic joint hypermobility and variants of connective tissue disorder to both conditions and to associated level of symptoms. Fibromyalgia and ME/CFS are both associated with inflammatory abnormalities¹⁰⁻¹¹ and dysautonomia¹²⁻¹⁴ (e.g. orthostatic intolerance, postural orthostatic tachycardia syndrome and orthostatic hypotension), which is also commonly observed in symptomatic hypermobility¹⁴⁻⁴⁸. In fact, autonomic dysfunction is proposed to mediate disabling symptoms in fibromyalgia and has an established association with variants of connective tissue and heightened interoceptive sensibility⁶⁰. Interoceptive sensibility is subjective measurement of the sense relating to one's own internal bodily sensations⁵⁸. While it is clear that there are associations between symptomatic hypermobility and both fibromyalgia and ME/CFS, the relationships between these conditions remain poorly understood. Ongoing research seeks to extend our observations reported here to determine how symptomatic hypermobility relates to autonomic and inflammatory induced changes in pain and fatigue in fibromyalgia and ME/CFS. Limitations of the present study include relatively small control group and difficulty in discriminating between pain-predominant and fatigue-predominant disease.

This paper adds further recognition to the high rates of hypermobility in fibromyalgia and ME/CFS. However, this is the first study to use multiple complementary assessments of joint hypermobility and variant connective tissue to explore these

relationships. A rich debate has been stimulated by a recent paper reporting the prevalence of EDS and JHS³³. While other forms of EDS are likely rare, the present study suggests hEDS is common among patients with pain and fatigue. Our control group is too small to make more than anecdotal statements regarding hEDS prevalence. However, approximately 1 in 5 of those meeting Brighton Criteria for joint hypermobility syndrome might endorse a diagnosis of hEDS and many patients appear to remain undiagnosed.

The classification of symptomatic joint hypermobility and variants of connective tissue is an evolving area^{29 31 61 62}. Importantly, this study reveals that distinct aspects of the diagnostic criteria for symptomatic hypermobility predict symptom severity in pain and fatigue conditions. From these data, it would appear that the Brighton Criteria predict Fibromyalgia and ME/CFS diagnosis and symptomatology. Interestingly, the Brighton Criteria make use of the historical account of joint laxity, which was highly associated with symptom severity, compared to current joint laxity, which is not included within the hEDS 2017 criteria (Criteria 1).

This relatively small study highlights the need for better recognition and accurate diagnosis in these poorly understood conditions. Fibromyalgia patients may wait on average almost a year after experiencing symptoms before presenting to a physician, and a diagnosis of fibromyalgia may take around 2.3 years, presenting to 3.7 different physicians, to be established⁶³. Once confirmed a fibromyalgia diagnosis may have mixed benefits for patients⁶⁴. Similar delays to diagnosis are observed for ME/CFS⁶⁵. The impact on quality of life in Fibromyalgia and ME/CFS is severe^{66 67}. Greater awareness among the scientific and medical community about

the overlapping nature of these conditions and their system-wide symptomatology will improve the appropriate diagnosis and multi-disciplinary treatment for patients⁶⁸. Studies underway will determine the wider role of variant connective tissue (of which joint hypermobility may be but a single manifestation) in relationship to autonomic and inflammatory induced changes in pain and fatigue in Fibromyalgia and ME/CFS (<https://doi.org/10.1186/ISRCTN78820481>) including interoceptive and neural mechanisms and the role of the transcriptome.

CONTRIBUTORSHIP AND GUARANTOR INFORMATION

Jessica Eccles, Neil Harrison, Hugo Critchley and Kevin Davies designed the study. Jessica Eccles, Kristy Themelis, Marisa Amato, Zdenka Cipinova, Lorraine Shah-Goodwin, Jean Timeyin, Thomas Batty and Charlotte Thompson collected data for the study. Beth Thompson, Robyn Stocks and Amy Pound processed data for the study. Jessica Eccles analysed data for the study with the assistance of Anna – Marie Jones. Jessica Eccles, Kevin Davies, Hugo Critchley, Beth Thompson, Anna Marie Jones and Neil Harrison drafted the manuscript. All authors approved the manuscript. Jessica Eccles acts a guarantor of the study. The guarantor accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

ACKNOWLEDGEMENTS

We wish to acknowledge the invaluable practical assistance of Valentina Toska and Mel Smith, the significant support of the Clinical Investigations Research Unit (Brighton and Sussex University Hospitals NHS Trust) and the editorial assistance of Robert Simonoff and A S Chamings. We would also like to acknowledge the dedication and support of Colin Barton from the Sussex & Kent ME/CFS Society and Janice Kent of ReMEMber.

CONFLICT OF INTEREST

No conflict of interest declared. All authors have completed the ICMJE Form for Disclosure of Potential Conflicts of Interest

COPYRIGHT/LICENSE FOR PUBLICATION

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, [a worldwide licence](#) to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

DATA SHARING

Deidentified participant data is available upon reasonable request from the corresponding author (ORCID ID <https://orcid.org/0000-0002-0062-1216>).

ETHICS APPROVAL

Ethical approval was obtained from London-Brighton & Sussex Research Ethics Committee (REF:17/LO/0845).

FUNDING

This project was primarily funded by a Versus Arthritis Grant (21994), with additional support provided by a studentship awarded by Action for M.E. and match-funded by Brighton and Sussex Medical School. The work was also supported by a charitable donation from the Fibroduck Foundation. Jessica Eccles was supported by the National Institute of Health Research (CL-2015-27-002).

The funder did not play a role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The researchers are independent from the funders and all authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

TRANSPARENCY

The manuscript's guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained.

REFERENCES

1. Jones GT, Atzeni F, Beasley M, et al. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. *Arthritis Rheumatol* 2015;67(2):568-75. doi: 10.1002/art.38905 [published Online First: 2014/10/18]
2. Katz RS, Heard AR, Mills M, et al. The prevalence and clinical impact of reported cognitive difficulties (fibrofog) in patients with rheumatic disease with and without fibromyalgia. *J Clin Rheumatol* 2004;10(2):53-8. doi: 10.1097/01.rhu.0000120895.20623.9f [published Online First: 2006/10/18]
3. Kravitz H, Katz R. Fibrofog and fibromyalgia: a narrative review and implications for clinical practice. *Rheumatol Int* 2015;35(7):1115-25. doi: 10.1007/s00296-014-3208-7
4. Hoffman D, Dukes E. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. *International journal of clinical practice* 2008;62(1):115-26.
5. Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. *Patient education and counseling* 2008;73(1):114-20.
6. Gerwyn M, Maes M. Mechanisms explaining muscle fatigue and muscle pain in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A review of recent findings. *Current rheumatology reports* 2017;19(1):1.
7. Van Oosterwijck J, Nijs J, Meeus M, et al. Pain inhibition and postexertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome: an experimental study. *Journal of internal medicine* 2010;268(3):265-78.

8. Hyland ME, Bacon AM, Lanario JW, et al. Symptom frequency and development of a generic functional disorder symptom scale suitable for use in studies of patients with irritable bowel syndrome, fibromyalgia syndrome or chronic fatigue syndrome. *Chronic Dis Transl Med* 2019;5(2):129-38. doi: 10.1016/j.cdtm.2019.05.003 [published Online First: 2019/08/02]
9. Natelson BH. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: Definitions, Similarities, and Differences. *Clin Ther* 2019;41(4):612-18. doi: 10.1016/j.clinthera.2018.12.016 [published Online First: 2019/02/24]
10. Backryd E, Tanum L, Lind AL, et al. Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. *Journal of pain research* 2017;10:515-25. doi: 10.2147/jpr.S128508 [published Online First: 2017/04/21]
11. Missailidis D, Annesley SJ, Fisher PR. Pathological Mechanisms Underlying Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Diagnostics (Basel, Switzerland)* 2019;9(3) doi: 10.3390/diagnostics9030080 [published Online First: 2019/07/25]
12. Newton JL, Okonkwo O, Sutcliffe K, et al. Symptoms of autonomic dysfunction in chronic fatigue syndrome. *QJM : monthly journal of the Association of Physicians* 2007;100(8):519-26. doi: 10.1093/qjmed/hcm057 [published Online First: 2007/07/10]
13. Miwa K. Cardiac dysfunction and orthostatic intolerance in patients with myalgic encephalomyelitis and a small left ventricle. *Heart and vessels*

2015;30(4):484-9. doi: 10.1007/s00380-014-0510-y [published Online First: 2014/04/17]

14. De Wandele I, Rombaut L, Leybaert L, et al. Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers-Danlos syndrome. *Seminars in arthritis and rheumatism* 2014;44(1):93-100. doi: 10.1016/j.semarthrit.2013.12.006 [published Online First: 2014/02/11]
15. Rudin NJ. Fibromyalgia. *Pain*: Springer 2019:693-97.
16. Castori M, Celletti C, Camerota F, et al. Chronic fatigue syndrome is commonly diagnosed in patients with Ehlers-Danlos syndrome hypermobility type/joint hypermobility syndrome. *Clinical and Experimental Rheumatology-Incl Supplements* 2011;29(3):597.
17. Rowe PC, Barron DF, Calkins H, et al. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. *The Journal of pediatrics* 1999;135(4):494-99.
18. Remvig L, Engelbert RH, Berglund B, et al. Need for a consensus on the methods by which to measure joint mobility and the definition of norms for hypermobility that reflect age, gender and ethnic-dependent variation: is revision of criteria for joint hypermobility syndrome and Ehlers-Danlos syndrome hypermobility type indicated? *Rheumatology (Oxford)* 2011;50(6):1169-71. doi: 10.1093/rheumatology/ker140
ker140 [pii] [published Online First: 2011/04/13]
19. Remvig L, Jensen DV, Ward RC. Epidemiology of general joint hypermobility and basis for the proposed criteria for benign joint hypermobility syndrome: review of the literature. *J Rheumatol* 2007;34(4):804-9. doi: 06/13/019 [pii] [published Online First: 2007/04/05]

20. Remvig L, Jensen DV, Ward RC. Are diagnostic criteria for general joint hypermobility and benign joint hypermobility syndrome based on reproducible and valid tests? A review of the literature. *J Rheumatol* 2007;34(4):798-803. doi: 06/13/018 [pii] [published Online First: 2007/02/14]
21. Grahame R. Time to take hypermobility seriously (in adults and children). *Rheumatology (Oxford)* 2001;40(5):485-7. [published Online First: 2001/05/24]
22. Castori M, Celletti C, Camerota F, et al. Chronic fatigue syndrome is commonly diagnosed in patients with Ehlers-Danlos syndrome hypermobility type/joint hypermobility syndrome. *Clin Exp Rheumatol* 2011;29(3):597-8. [published Online First: 2011/07/05]
23. Barron DF, Cohen BA, Geraghty MT, et al. Joint hypermobility is more common in children with chronic fatigue syndrome than in healthy controls. *J Pediatr* 2002;141(3):421-5. doi: 10.1067/mpd.2002.127496 [published Online First: 2002/09/10]
24. Ofluoglu D, Gunduz OH, Kul-Panza E, et al. Hypermobility in women with fibromyalgia syndrome. *Clin Rheumatol* 2006;25(3):291-3. doi: 10.1007/s10067-005-0040-1 [published Online First: 2005/10/18]
25. Chopra P, Tinkle B, Hamonet C, et al. Pain management in the Ehlers-Danlos syndromes. *Am J Med Genet C Semin Med Genet* 2017;175(1):212-19. doi: 10.1002/ajmg.c.31554 [published Online First: 2017/02/12]
26. Clinch J, Deere K, Sayers A, et al. Epidemiology of generalized joint laxity (hypermobility) in fourteen-year-old children from the UK: a population-based evaluation. *Arthritis Rheum* 2011;63(9):2819-27. doi: 10.1002/art.30435 [published Online First: 2011/05/07]

27. Mulvey MR, Macfarlane GJ, Beasley M, et al. Modest association of joint hypermobility with disabling and limiting musculoskeletal pain: results from a large-scale general population-based survey. *Arthritis Care Res (Hoboken)* 2013;65(8):1325-33. doi: 10.1002/acr.21979 [published Online First: 2013/02/13]
28. Castori M. Ehlers-danlos syndrome, hypermobility type: an underdiagnosed hereditary connective tissue disorder with mucocutaneous, articular, and systemic manifestations. *ISRN Dermatol* 2012;2012:751768. doi: 10.5402/2012/751768 [published Online First: 2012/12/12]
29. Castori M, Tinkle B, Levy H, et al. A framework for the classification of joint hypermobility and related conditions. *Am J Med Genet C Semin Med Genet* 2017;175(1):148-57. doi: 10.1002/ajmg.c.31539 [published Online First: 2017/02/02]
30. Grahame R, Bird HA, Child A. The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). *J Rheumatol* 2000;27(7):1777-9.
31. Tinkle BT, Bird HA, Grahame R, et al. The lack of clinical distinction between the hypermobility type of Ehlers-Danlos syndrome and the joint hypermobility syndrome (a.k.a. hypermobility syndrome). *Am J Med Genet A* 2009;149A(11):2368-70. doi: 10.1002/ajmg.a.33070 [published Online First: 2009/10/21]
32. Copetti M, Morlino S, Colombi M, et al. Severity classes in adults with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders: a pilot study of 105 Italian patients. *Rheumatology (Oxford)* 2019;58(10):1722-30. doi: 10.1093/rheumatology/kez029 [published Online First: 2019/02/21]

33. Demmler JC, Atkinson MD, Reinhold EJ, et al. Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case–control comparison. *BMJ Open* 2019;9(11)
34. Rombaut L, Malfait F, Cools A, et al. Musculoskeletal complaints, physical activity and health-related quality of life among patients with the Ehlers–Danlos syndrome hypermobility type. *Disability and Rehabilitation* 2010;32(16):1339-45. doi: 10.3109/09638280903514739
35. Bovet C, Carlson M, Taylor M. Quality of life, unmet needs, and iatrogenic injuries in rehabilitation of patients with Ehlers-Danlos Syndrome hypermobility type/Joint Hypermobility Syndrome. *Am J Med Genet A* 2016;170(8):2044-51. doi: 10.1002/ajmg.a.37774 [published Online First: 2016/06/09]
36. Castori M, Camerota F, Celletti C, et al. Quality of life in the classic and hypermobility types of Ehlers-Danlos syndrome [corrected]. *Ann Neurol* 2010;67(1):145-6; author reply 46-7. doi: 10.1002/ana.21934 [published Online First: 2010/02/27]
37. Fatoye F, Palmer S, Macmillan F, et al. Pain intensity and quality of life perception in children with hypermobility syndrome. *Rheumatol Int* 2012;32(5):1277-84. doi: 10.1007/s00296-010-1729-2 [published Online First: 2011/01/27]
38. Johannessen EC, Reiten HS, Lovaas H, et al. Shoulder function, pain and health related quality of life in adults with joint hypermobility syndrome/Ehlers-Danlos syndrome-hypermobility type. *Disabil Rehabil* 2016;38(14):1382-90. doi: 10.3109/09638288.2015.1102336 [published Online First: 2016/01/30]

39. Junge T, Henriksen P, Hansen S, et al. Generalised joint hypermobility and knee joint hypermobility: prevalence, knee joint symptoms and health-related quality of life in a Danish adult population. *Int J Rheum Dis* 2019;22(2):288-96. doi: 10.1111/1756-185X.13205 [published Online First: 2017/10/28]
40. Juul-Kristensen B, Ostengaard L, Hansen S, et al. Generalised joint hypermobility and shoulder joint hypermobility, - risk of upper body musculoskeletal symptoms and reduced quality of life in the general population. *BMC Musculoskelet Disord* 2017;18(1):226. doi: 10.1186/s12891-017-1595-0 [published Online First: 2017/06/01]
41. Morlino S, Dordoni C, Sperduti I, et al. Italian validation of the functional difficulties questionnaire (FDQ-9) and its correlation with major determinants of quality of life in adults with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorder. *Am J Med Genet B Neuropsychiatr Genet* 2019;180(1):25-34. doi: 10.1002/ajmg.b.32698 [published Online First: 2018/11/25]
42. Mu W, Muriello M, Clemens JL, et al. Factors affecting quality of life in children and adolescents with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders. *Am J Med Genet A* 2019;179(4):561-69. doi: 10.1002/ajmg.a.61055 [published Online First: 2019/02/01]
43. Pacey V, Tofts L, Adams RD, et al. Quality of life prediction in children with joint hypermobility syndrome. *J Paediatr Child Health* 2015;51(7):689-95. doi: 10.1111/jpc.12826 [published Online First: 2015/01/28]
44. Rombaut L, Malfait F, Cools A, et al. Musculoskeletal complaints, physical activity and health-related quality of life among patients with the Ehlers-

- Danlos syndrome hypermobility type. *Disabil Rehabil* 2010;32(16):1339-45.
doi: 10.3109/09638280903514739 [published Online First: 2010/02/17]
45. Schmidt H, Pedersen TL, Junge T, et al. Hypermobility in Adolescent Athletes: Pain, Functional Ability, Quality of Life, and Musculoskeletal Injuries. *J Orthop Sports Phys Ther* 2017;47(10):792-800. doi: 10.2519/jospt.2017.7682
[published Online First: 2017/09/17]
46. Grahame R. Hypermobility: an important but often neglected area within rheumatology. *Nature clinical practice Rheumatology* 2008;4(10):522-4. doi: 10.1038/ncprheum0907 [published Online First: 2008/09/03]
47. Castori M, Voermans NC. Neurological manifestations of Ehlers-Danlos syndrome(s): A review. *Iran J Neurol* 2014;13(4):190-208.
48. Hakim A, O'Callaghan C, De Wandele I, et al. Cardiovascular autonomic dysfunction in Ehlers-Danlos syndrome-Hypermobility type. *Am J Med Genet C Semin Med Genet* 2017;175(1):168-74. doi: 10.1002/ajmg.c.31543 [published Online First: 2017/02/06]
49. Nijs J, Aerts A, De Meirleir K. Generalized joint hypermobility is more common in chronic fatigue syndrome than in healthy control subjects. *J Manipulative Physiol Ther* 2006;29(1):32-9. doi: 10.1016/j.jmpt.2005.11.004 [published Online First: 2006/01/07]
50. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis Care Res (Hoboken)* 2010;62(5):600-10. doi: 10.1002/acr.20140 [published Online First: 2010/05/13]

51. Carruthers BM, Jain AK, De Meirleir KL, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. *Journal of chronic fatigue syndrome* 2003;11(1):7-115.
52. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. *Annals of internal medicine* 1994;121(12):953-59.
53. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Archives of neurology* 1989;46(10):1121-3. doi: 10.1001/archneur.1989.00520460115022 [published Online First: 1989/10/01]
54. Melzack R. The short-form McGill pain questionnaire. *Pain* 1987;30(2):191-97.
55. Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. *Clinical Infectious Diseases* 1994;18(Supplement_1):S79-S83.
56. Larson RD. Psychometric properties of the modified fatigue impact scale. *International journal of MS care* 2013;15(1):15-20.
57. Leavitt F, Katz RS. Development of the mental clutter scale. *Psychological reports* 2011;109(2):445-52.
58. Garfinkel SN, Seth AK, Barrett AB, et al. Knowing your own heart: distinguishing interoceptive accuracy from interoceptive awareness. *Biological psychology* 2015;104:65-74.
59. Porges S. Body perception questionnaire. *Laboratory of Developmental Assessment, University of Maryland* 1993

60. Aslanyan D, Iodice V, Davies KA, et al. Dissociative experiences in fibromyalgia are mediated by symptoms of autonomic dysfunction. *medRxiv* 2019:19006320.
61. Castori M, Hakim A. Contemporary approach to joint hypermobility and related disorders. *Curr Opin Pediatr* 2017;29(6):640-49. doi: 10.1097/MOP.0000000000000541 [published Online First: 2017/09/15]
62. Guarnieri V, Castori M. Clinical Relevance of Joint Hypermobility and Its Impact on Musculoskeletal Pain and Bone Mass. *Curr Osteoporos Rep* 2018;16(4):333-43. doi: 10.1007/s11914-018-0460-x [published Online First: 2018/06/20]
63. Choy E, Perrot S, Leon T, et al. A patient survey of the impact of fibromyalgia and the journey to diagnosis. *BMC health services research* 2010;10:102. doi: 10.1186/1472-6963-10-102 [published Online First: 2010/04/28]
64. Undeland M, Malterud K. The fibromyalgia diagnosis: hardly helpful for the patients? A qualitative focus group study. *Scand J Prim Health Care* 2007;25(4):250-5. doi: 10.1080/02813430701706568 [published Online First: 2007/11/29]
65. Comiskey C, Larkan F. A national cross-sectional survey of diagnosed sufferers of myalgic encephalomyelitis/chronic fatigue syndrome: pathways to diagnosis, changes in quality of life and service priorities. *Irish journal of medical science* 2010;179(4):501-05.
66. Hvidberg MF, Brinth LS, Olesen AV, et al. The health-related quality of life for patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *PloS one* 2015;10(7):e0132421.

67. Birtane M, Uzunca K, Taştekin N, et al. The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis by using SF-36 Health Survey. *Clinical rheumatology* 2007;26(5):679-84.
68. Practitioners RCoG. The Ehlers-Danlos Syndromes Toolkit 2019 [Available from: <https://www.rcgp.org.uk/eds> accessed November 9th 2019.

FIGURE LEGEND

Figure 1. Interaction of joint hypermobility syndrome on the relationship between interoceptive sensibility and Fibromyalgia and or ME/CFS

Brighton Criteria Met for Joint Hypermobility Syndrome

